Maho Tanaka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Maho Tanaka has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Satoshi Numazawa
Department of Toxicology, Showa Medical University Graduate School of Pharmacy, Tokyo, Japan
2 shared publications - Kenji Momo
Division of Clinical Research, Department of Hospital Pharmaceutics, School of Pharmacy Showa Medical University Tokyo Japan
1 shared publication - Masato Komuro
Japan Institute for Health Security, Tokyo, Japan
1 shared publication Takahiro Nishimura
Department of Pharmacy, National Center for Global Health and Medicine, Japan Institute for Health Security, Tokyo, Japan
1 shared publication- Takahiro Nishimura
Department of Pharmacy National Center for Global Health and Medicine Tokyo Japan
1 shared publication Yasushi Kojima
Department of Gastroenterology, National Center for Global Health and Medicine, Japan Institute for Health Security, Tokyo, Japan
1 shared publication
Latest Publications
- 8 September 2025
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
Usefulness of hydrocortisone prophylaxis for oxaliplatin-induced hypersensitivity reactions: A retrospective study
Introduction: Oxaliplatin is a platinum-based drug widely used for treating colorectal cancer. However, its use is often complicated by hypersensitivity reactions and other adverse effects, including peripheral neuropathy and myelosuppression. We evaluated the efficacy of prophylactic hydrocortisone administration in preventing hypersensitivity reactions during oxaliplatin therapy in patients with colorectal cancer. Methods: Patients who received oxaliplatin between January 2017 and December 2023 were retrospectively analyzed. Among them, 53 received 100 mg of hydrocortisone as a preventive measure when the cumulative oxaliplatin dose exceeded 400 mg/m 2 or if they experienced a treatment interruption of >8 weeks. We compared the incidence and severity of hypersensitivity reactions, as well as cumulative oxaliplatin dose, between patients who received routine premedication only (the Routine group) and those who received additional hydrocortisone prophylaxis (the Prophylaxis group). Results: Overall, 370 patients were included in the study. Hypersensitivity reactions occurred in 23 patients (18 in the Routine group and 5 in the Prophylaxis group), with a significantly higher cumulative dose of oxaliplatin in the Prophylaxis group (644 vs. 1383 mg/m 2 , p = 0.0032). Severe reactions were observed only in the Routine group. Treatment discontinuation owing to hypersensitivity reactions was more common in the Routine group (five patients) than in the Prophylaxis group (one patient). Conclusions: Prophylactic administration of hydrocortisone may promote oxaliplatin treatment continuation. This approach is proposed as a potential strategy for preventing oxaliplatin-induced hypersensitivity reactions.
- 8 September 2025
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
Usefulness of hydrocortisone prophylaxis for oxaliplatin-induced hypersensitivity reactions: A retrospective study
Introduction: Oxaliplatin is a platinum-based drug widely used for treating colorectal cancer. However, its use is often complicated by hypersensitivity reactions and other adverse effects, including peripheral neuropathy and myelosuppression. We evaluated the efficacy of prophylactic hydrocortisone administration in preventing hypersensitivity reactions during oxaliplatin therapy in patients with colorectal cancer. Methods: Patients who received oxaliplatin between January 2017 and December 2023 were retrospectively analyzed. Among them, 53 received 100 mg of hydrocortisone as a preventive measure when the cumulative oxaliplatin dose exceeded 400 mg/m 2 or if they experienced a treatment interruption of >8 weeks. We compared the incidence and severity of hypersensitivity reactions, as well as cumulative oxaliplatin dose, between patients who received routine premedication only (the Routine group) and those who received additional hydrocortisone prophylaxis (the Prophylaxis group). Results: Overall, 370 patients were included in the study. Hypersensitivity reactions occurred in 23 patients (18 in the Routine group and 5 in the Prophylaxis group), with a significantly higher cumulative dose of oxaliplatin in the Prophylaxis group (644 vs. 1383 mg/m 2 , p = 0.0032). Severe reactions were observed only in the Routine group. Treatment discontinuation owing to hypersensitivity reactions was more common in the Routine group (five patients) than in the Prophylaxis group (one patient). Conclusions: Prophylactic administration of hydrocortisone may promote oxaliplatin treatment continuation. This approach is proposed as a potential strategy for preventing oxaliplatin-induced hypersensitivity reactions.
- Open Access
- 25 August 2025
- Published by Wiley in Clinical Case Reports
- Vol. 13 (9) , 93
A Case of Metronidazole‐Induced Encephalopathy: Can Encephalopathy be Distinguished From Delirium Like Symptoms?
Although the treatment strategies differ significantly, metronidazole‐induced encephalopathy and delirium manifest with similar clinical symptoms. Therefore, the potential risk of encephalopathy should be considered when treating patients with delirium.
- 25 August 2025
- Published by Wiley in Clinical Case Reports
- Vol. 13 (9) , 93
Open AccessA Case of Metronidazole‐Induced Encephalopathy: Can Encephalopathy be Distinguished From Delirium Like Symptoms?
Although the treatment strategies differ significantly, metronidazole‐induced encephalopathy and delirium manifest with similar clinical symptoms. Therefore, the potential risk of encephalopathy should be considered when treating patients with delirium.